Welcome to Current Partnering: The Source of Best Practice for Dealmakers

Subscribe to the monthly CurrentPartnering newsletter

CurrentPartnering is a publisher of business development best practice and deal terms reports

A list of our latest reports is provided below or view a full list of CurrentPartnering reports.

JUST PUBLISHED: Partnering Agreements with....

Abbott, Actavis, Alcon, Allergan, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Chugai, CSL, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Forest, Genentech, Genzyme, Gilead, GlaxoSmithKline, Hospira, Johnson & Johnson, Lundbeck, Menarini, Merck & Co, Merck Serono, Mitsubishi Tanabe, Mylan, Novartis, Novo Nordisk, Nycomed, Otsuka, Prizer, Ratiopharm, Roche, Sanofi-Aventis, Servier, Shire, Solvay, Takeda, Teva, UCB, Watson.

Providing detailed understanding and analysis of bigpharma companies entering partnering deals, including access to actual contract agreements

NEW REPORT: Drug Delivery Partnering Agreements in Pharma and Biotech

Providing detailed understanding and analysis of how and why companies enter drug delivery partnering deals, plus access to actual contract agreements find out more now

NEW REPORT: Partnering Agreements in Diagnostics

Providing detailed understanding and analysis of how and why companies enter diagnostic partnering deals, plus access to actual diagnostic agreements find out more now here

NEW REPORT: Oncology Partnering Agreements in Pharma, Biotech and Diagnostics

Providing detailed understanding and analysis of how and why companies enter oncology partnering deals, plus access to actual oncology agreements order here now

REVISED AND UPDATED: Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics

Provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies order here today

NEW REPORT: Option & Evaluation Agreements in Pharma and Biotech

Providing detailed understanding and analysis of how and why companies enter option and evaluation deals, plus access to actual option and evaluation agreements order now here

NEW REPORT: Royalty Financing Agreements in Pharma, Biotech and Diagnostics

Providing detailed understanding and analysis of how and why companies enter royalty financing deals, plus access to actual royalty financing agreements order here

OTHER RECENT REPORTS

Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 2nd edition

Providing detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals, plus access to actual agreements Co-promotion and Co-marketing Agreements in Biopharma

Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition

Providing detailed understanding and analysis of how and why companies enter M&A deals, plus access to actual M&A agreements Merger and Acquisition Agreements in Biopharma

Product and Asset Purchase Agreements in Pharm, Biotech & Diagnostics

Providing detailed understanding and analysis of how and why companies enter asset purchase deals, plus 100s of asset purchase agreements order now

Other reports from CurrentPartnering

Plus 100s of other reports and books on partnering best practice available and updated weekly Browse reports


IN THE NEWS

In the news: Partnering continues to gain momentum into 2010

Recent deals include Starpharma and Eli Lilly sign new drug delivery collaboration; Cephalon to buy generic firm Mepha for $590 million; Amgen and Stiefel in Enbrel promotion pact; Imperial Innovations licences meningjitis B vaccine to Novartis - more news


NETWORKS NOW INCLUDES LINKEDIN DISCUSSION GROUPS

CurrentPartnering's LinkedIn group now includes active discussion and news streams.

CurrentPartnering Networks - a series of online social network groups for the biopharma dealmaker - includes LinkedIn, Plaxo, Facebook, Twitter...

Join now!


ARTICLES

Royalty Rates For Technology Transactions

An interesting study was carried out between 1990 and 2007 which discovered that the most frequently negotiated royalty rate is 5% of net sales - read now

Big Pharma seeks to insulate itself from impact of ‘patent cliff’

As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff’, Big Pharma* is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines more on this article


EVENTS

Partnering events for winter 2010

Next up: 10th MedTech Investing Europe Conference; BIO-Windhover 2010; Pharmaceutical Strategic Outlook 2010; BioNetwork East 2010; EuroPLX 42 Valletta more events


PEOPLE

People on the move

Updated daily to provide the latest on career moves during winter 2010 career updates


RESOURCES

The best of the web for dealmakers

The best partnering resources available online - from software tools to partnering quotes to reference library View resources

SCORECARD

The highest value partnering and M&A deals of 2009 more scorecards

Scorecard Index

scorecardside

Deal term reports

The information you provide is excellent and we look forward to doing more business with you in the future

...You have published very timely and interesting materials.... I am excited.... It is an excellent publication and pretty well up to date...

clickable15

clickable14

clickable13

clickable2

clickable12

clickable1

clickable

clickable11

clickable10

clickable5

clickable9

clickable8

clickable7

clickable6

clickable4

clickable3


CurrentPartnering Reports

The latest reports on best practise for dealmakers available from CurrentPartnering


Contact us

Email now

or call us:

+44 7896 656732

Did you know?

Discover the terms that drive the deal making world. See Glossary


Term of the week...


Supplementary Protection Certificate (SPC) - granted to extend the period of protection under a patent in respect of a specified pharmaceutical (or plant protection) product that is protected by the patent